Is Organon & Co halal to invest in?

According to Musaffa's Shariah screening methodology, Organon & Co (OGN) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Organon & Co a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Organon & Co using these criteria to determine its compliance status.

Can Muslims buy shares of Organon & Co?

Muslim investors may consider investing in Organon & Co if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Organon & Co classified as NOT HALAL?

Musaffa determines the Shariah status of Organon & Co by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Organon & Co updated?

The Shariah compliance status of Organon & Co may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Organon & Co become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Organon & Co?

You can check the latest Shariah compliance status of Organon & Co on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

OGN Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 08, 2026

Report Source: 2026 1st Quarter Report

Organon & Co. Stock Analysis OGN

United States Health Care Mid Cap Report: Q1, 2026

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 10,000 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. The company has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. The company has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. The company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Key Statistics of Organon & Co (OGN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$13.34$13.41

Today's Open

$13.37

Volume

3.28M

P/E Ratio (TTM)

18.82

52 Week Range

$5.69$13.44

Market Cap

3.51B

Avg. Volume

15.42M

Dividend Yield

0.63%

Financial Metrics & Statements of Organon & Co (OGN)

FAQ's for Organon & Co (OGN)

According to Musaffa’s Shariah screening methodology, Organon & Co (OGN) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.